Actions of thalidomide in producing vascular relaxations

European Journal of Pharmacology

Volumn 644, Issue 1-3, 2010, Pages 113-119

  Seto, Sai Wang ^a   Bexis, Sotiria ^a   McCormick, P Aiden ^b   Docherty, James R ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

1 adrenoceptor; Blood pressure; Hypotension; Mibefradil; Postural hypotension; T type calcium channels, NNC 55 0396; Thalidomide

Indexed keywords

ALPHA 1A ADRENERGIC RECEPTOR; ALPHA 1B ADRENERGIC RECEPTOR; CAFFEINE; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL T TYPE; CALPHOSTIN; GLIBENCLAMIDE; MIBEFRADIL; MITOGEN ACTIVATED PROTEIN KINASE P38; NIFEDIPINE; NNC 55 0396; PROTEIN KINASE C; THALIDOMIDE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG RESPONSE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; MALE; MUSCLE ISOMETRIC CONTRACTION; NONHUMAN; PRIORITY JOURNAL; RAT; VASODILATATION;

ANGIOGENESIS INHIBITORS; ANIMALS; AORTA; BENZIMIDAZOLES; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, T-TYPE; CYCLOPROPANES; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; NAPHTHALENES; PHENYLEPHRINE; RATS; RATS, WISTAR; THALIDOMIDE; VASOCONSTRICTOR AGENTS; VASODILATION;

EID: 77955770724     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.06.035     Document Type: Article

References (41)

1. Askari B., Ferreri N.R. Regulation of prostacyclin synthesis by angiotensin II and TNF-α in vascular smooth muscle. Prostaglandins Other Lipid Mediat. 2001, 263:175-187.
2. Baidas S.M., Winer E.P., Fleming G.F., Harris L., Pluda J.M., Crawford J.G., Yamauchi H., Isaacs C., Hanfelt J., Tefft M., Flockhart D., Johnson M.D., Hawkins M.J., Lippman M.E., Hayes D.F. Phase II evaluation of thalidomide in patients with metastatic breast cancer. J. Clin. Oncol. 2000, 18:2710-2717.
3. Ball C.J., Wilson D.P., Turner S.P., Saint D.A., Beltrame J.F. Heterogeneity of L- and T-channels in the vasculature: rationale for the efficacy of combined L- and T-blockade. Hypertension 2009, 53:654-660.
4. Bauer K.S., Dixon S.C., Figg W.D. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem. Pharmacol. 1998, 55:1827-1834.
5. Browne M., Connolly C., Docherty J.R. Vascular actions of 17β-oestradiol in rat aorta and mesenteric artery. J. Auton. Pharmacol. 1999, 19:291-299.
6. Celis R., Torre-Martinez G., Torre-Amione G. Evidence for activation of immune system in heart failure: is there a role for anti-inflammatory therapy?. Curr. Opin. Cardiol. 2008, 23:254-260.
7. Cheung Y.D., Barnett D.B., Nahorski S.R. [3H]Rauwolscine and [3H]yohimbine binding to rat cerebral and human platelet membranes: possible heterogeneity of α2-adrenoceptors. Eur. J. Pharmacol. 1982, 84:79-85.
8. Cleary L., Vandeputte C., Kelly J.G., Docherty J.R. Actions of R- and S-verapamil and nifedipine on rat vascular and intestinal smooth muscle. Auton. Autacoid Pharmacol. 2004, 24:63-67.
9. Clozel J.P., Ertel E.A., Ertel S.I. Voltage-gated T-type Ca2+ channels and heart failure. Proc. Assoc. Am. Physicians 1999, 111:429-437.
10. Connaughton S., Docherty J.R. Functional evidence for heterogeneity of peripheral prejunctional α2-adrenoceptors. Br. J. Pharmacol. 1990, 101:285-290.
11. Docherty J.R. Subtypes of functional α1-adrenoceptor. Cell. Mol. Life Sci. 2010, 67:405-417.
12. Glasser S.P. The relevance of T-type calcium antagonists: a profile of mibefradil. J. Clin. Pharmacol. 1998, 38:659-669.
13. Hattori Y., Kawasaki H., Kanno M. Increased contractile responses to endothelin-1 and U46619 via a protein kinase C-mediated nifedipine-sensitive pathway in diabetic rat aorta. Res. Commun. Mol. Pathol. Pharmacol. 1999, 104:73-80.
14. Hayashi K., Wakino S., Homma K., Sugano N., Saruta T. Pathophysiological significance of T-type Ca2+ channels: role of T-type Ca2+ channels in renal microcirculation. J. Pharmacol. Sci. 2005, 99:221-227.
15. 2+ channel subtypes and pharmacology in the kidney. Circ. Res. 2007, 100:342-353.
16. Hefti F., Clozel J.P., Osterrieder W. Antihypertensive properties of the novel calcium antagonist (1 S, 2 S)-2-[2-[[3-(2-benzimidazolyl)propyl]methylamino] ethyl]-6-fluoro-1, 2, 3, 4-tetrahydro-1-isopropyl-2-naphthyl methoxyacetate dihydrochloride in rat models of hypertension. Comparison with verapamil. Arzneimittelforschung 1990, 40:417-421.
17. Jackson C.V., Karow A.M., Carrier G.O. Influence of dimethyl sulfoxide (Me2SO) on vascular smooth muscle. Arch. Int. Pharmacodyn. Thér. 1979, 237:4-15.
18. Joglekar S., Levin M. The promise of thalidomide: evolving indications. Drugs Today (Barc) 2004, 40:197-204.
19. Kedzior K., Szczepanska R., Kocic I. Contribution of NO, ATP-sensitive K+ channels and prostaglandins to adenosine receptor agonists-induced relaxation of the tail artery. Pharmacol. Rep. 2009, 61:330-334.
20. Mangoni M.E., Traboulsie A., Leoni A.-L., Couette B., Marger L., Quang K.L., Kupfer E., Cohen-Solal A., Vilar J., Shin H.-S., Escande D., Charpentier F., Nargeot J., Lory P. Bradycardia and slowing of the atrioventricular conduction in mice lacking CaV3.1/1α1G T-type calcium channels. Circ. Res. 2006, 98:1422-1430.
21. Massett M.P., Ungvari Z., Csiszar A., Kaley G., Koller A. Different roles of PKC and MAP kinases in arteriolar constrictions to pressure and agonists. Am. J. Physiol. Heart Circ. Physiol. 2002, 283:H2282-H2287.
22. Mayer B., Holmer S.R., Hengstenberg C., Lieb W., Pfeifer M., Schunkert H. Functional improvement in heart failure patients treated with beta-blockers is associated with a decline of cytokine levels. Int. J. Cardiol. 2005, 103:182-186.
23. McAuley I.W., Kim N.N., Min K., Goldstein I., Traish A.M. Intracavernosal sildenafil facilitates penile erection independent of the nitric oxide pathway. J. Androl. 2001, 22:623-628.
24. Meredith P.A. Is postural hypotension a real problem with antihypertensive medication?. Cardiology 2001, 96:19-24.
25. Michel A.D., Loury D.N., Whiting R.L. Identification of a single α1-adrenoceptor corresponding to the α1A-subtype in rat submaxillary gland. Br. J. Pharmacol. 1989, 98:883-889.
26. Moreira A.L., Sampaio E.P., Zmuidzinas A., Frindt P., Smith K.A., Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor α by enhancing mRNA degradation. J. Exp. Med. 1993, 177:1675-1680.
27. Moritz A., Radtke O.A., Gust R., Glusa E., Pertz H.H. Characterisation of the relaxant response to raloxifene in porcine coronary arteries. Eur. J. Pharmacol. 2006, 545:153-160.
28. Mulvany M.J., Warshaw D.M. The active tension-length curve of vascular smooth muscle related to its cellular components. J. Gen. Physiol. 1979, 74:85-104.
29. Neylon C.B., Summers R.J. [3H]-rauwolscine binding to α2-adrenoceptors in the mammalian kidney: apparent receptor heterogeneity between species. Br. J. Pharmacol. 1985, 85:349-359.
30. Orea-Tejeda A., Arrieta-Rodríguez O., Castillo-Martínez L., Rodríguez-Reyna T., Asensio-Lafuente E., Granados-Arriola J., Dorantes-García J. Effects of thalidomide treatment in heart failure patients. Cardiology 2007, 108:237-242.
31. Rao K.V. Lenalidomide in the treatment of multiple myeloma. Am. J. Health Syst. Pharm. 2007, 64:1799-1807.
32. Richard S. Vascular effects of calcium channel antagonists: new evidence. Drugs 2005, 65:1-10.
33. Seto S.W., Docherty J.R. Effects of T-type Calcium Channel Blockers and Thalidomide on Contractions of Rat Vas Deferens 2009, (Proceedings of the British Pharmacological Society at http://www.pa2online.org/abstracts/Vol7Issue2abst030P.pdf).
34. Seto S.W., Kwan Y.W., Ngai S.M. Modulatory effect of interleukin-1beta on rat isolated basilar artery contraction. Eur. J. Pharmacol. 2006, 531:238-245.
35. Seto S.W., Bexis S., McCormick P.A., Docherty J.R. Investigation of Vascular Relaxations Produced by Thalidomide 2009, (Proceedings of the British Pharmacological Society at http://www.pa2online.org/abstracts/Vol7Issue2abst007P.pdf).
36. Stevens T., Morris K., McMurtry I.F., Zamora M., Tucker A. Pulmonary and systemic vascular responsiveness to TNF-α in conscious rats. J. Appl. Physiol. 1993, 74:1905-1910.
37. Summers S.M., Hayashi Y., Nguyen S.V., Nguyen T.M., Purdy R.E. Hindlimb unweighting induces changes in the p38MAPK contractile pathway of the rat abdominal aorta. J. Appl. Physiol. 2009, 107:121-127.
38. Varker K.A., Campbell J., Shah M.H. Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors. Cancer Chemother. Pharmacol. 2008, 61:661-668.
39. Walker S.L., Waters M.F., Lockwood D.N. The role of thalidomide in the management of erythema nodosum leprosum. Lepr. Rev. 2007, 78:197-215.
40. Wang R., Karpinski E., Pang P.K. Two types of calcium channels in isolated smooth muscle cells from rat tail artery. Am. J. Physiol. 1989, 256:H1361-H1368.
41. Yasui K., Kobayashi N., Yamazaki T., Agematsu K. Thalidomide as an immunotherapeutic agent: the effects on neutrophil-mediated inflammation. Curr. Pharm. Des. 2005, 11:395-401.